Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 12,222 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Sarcopenia
Interventions: bimagrumab, placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 70 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Little Rock, Arkansas • Cypress, California • La Jolla, California + 14 more

Conditions: Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer, Triple Negative Breast Cancer
Interventions: DKY709, PDR001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Multiple Myeloma
Interventions: M-VTD-PACE, TT3-LITE Regimen (L-TT3); Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Carfilzomib, Dexamethasone, Nivolumab, Pelareorep; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Salt Lake City, Utah

Conditions: Pancreatic Carcinoma
Interventions: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Sclerosis, Cognitive Dysfunction, Memory Disorders, Memory Impairment, Memory Dysfunction
Interventions: Home Based Self- management and Cognitive Training Changes lives in Multiple Sclerosis (HOBSCOTCH-MS); Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 20 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Wrinkle, Facial and Neck Skin Laxity
Interventions: micro-excisional skin removal with coring needle; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Sacramento, California • Miami, Florida • Chestnut Hill, Massachusetts + 3 more

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions: 18-NaF PET, DCE-MRI, 18-FDG PET/CT; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: E. Coli Strain M17 Probiotic; Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Disability Physical, Brain Injuries, Stroke, Spinal Cord Injuries, Multiple Sclerosis, Paralysis
Interventions: Using adaptive device.; Device
Lead sponsor: Madonna Rehabilitation Hospital; Other
Eligibility: 1 Year to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Multiple Myeloma
Interventions: Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone, Bortezomib; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 4
States / cities: Tampa, Florida • Westwood, Kansas • Boston, Massachusetts + 1 more

Conditions: Type 2 Diabetes
Interventions: Colesevelam hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 46
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Carmichael, California + 43 more

Conditions: Benign Prostatic Hyperplasia
Interventions: Microspheres; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Sclerosis
Interventions: Polyphenon E; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Acute Kidney Injury
Interventions: THR-184, Placebo; Drug
Lead sponsor: Thrasos Innovation, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 26 more

Conditions: Multiple Sclerosis, Stroke
Interventions: Movement to Music, Adapted Yoga; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: darbepoetin alfa, epoetin alfa; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Arthritis, Rheumatoid
Interventions: ofatumumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Fort Lauderdale, Florida • New York, New York + 1 more

Conditions: COVID-19
Interventions: ALG-097558; Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Carcinoma, Hepatocellular
Interventions: Stereotactic Body Radiation; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, Secondary Central Nervous System Lymphoma
Interventions: Magnetic Resonance Imaging, Neurocognitive Assessment, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • San Diego, California + 12 more

Conditions: Osteoarthritis, Post-traumatic Arthritis
Interventions: ATTUNE TKA with ATTUNE RUI, ATTUNE TKA with ATTUNE SUI; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: La Jolla, California • Wilkes-Barre, Pennsylvania

Conditions: Infections, Papillomavirus
Interventions: Cervarix™, Havrix™-based investigational formulation; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 18,729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 50
States / cities: Birmingham, Alabama • Fountain Valley, California • San Diego, California + 39 more

Search by objective public record fields.

Dose Range Finding Study of Bimagrumab in Sarcopenia

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer

HOBSCOTCH-MS-Efficacy Trial

Evaluation of Safety and Efficacy of Micro-coring Device for Treatment of Facial Wrinkles and Skin Laxity

Imaging in MGUS, SMM and MM

Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS)

Impact of Custom Assistive and Adaptive Technology in Rehabilitation

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

Safety of Polyphenon E in Multiple Sclerosis Pilot Study

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Lakeshore Examination of Activity and Disability Exercise Response Study

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Dose Escalation Study for Primary Hepatocellular Carcinoma

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus

ATTUNE Single-Use Instrumentation vs. ATTUNE Reusable Instrumentation in Primary Total Knee Arthroplasty

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18